Loading clinical trials...
Loading clinical trials...
Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A
Conditions
Interventions
PEGylated Recombinant Factor VIII
PEGylated Recombinant Factor VIII
+1 more
Locations
83
United States
Phoenix Childrens Hospital
Phoenix, Arizona, United States
Arizona Hemophilia & Thrombosis Center, located within The University of Arizona Cancer Center
Tucson, Arizona, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
University of Florida College of Medicine
Gainesville, Florida, United States
Emory University-ECC
Atlanta, Georgia, United States
Start Date
November 23, 2015
Primary Completion Date
August 5, 2018
Completion Date
August 5, 2018
Last Updated
May 25, 2021
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Baxalta now part of Shire
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions